Ad
related to: sando k prescribing guidelines
Search results
Results From The WOW.Com Content Network
Side effects can include gastrointestinal discomfort, including nausea and vomiting, diarrhea, and bleeding of the digestive tract. [medical citation needed]Overdoses cause hyperkalemia, which can lead to paresthesia, cardiac conduction blocks, fibrillation, arrhythmias, and sclerosis.
Very common (10-100% incidence) adverse effects include: Nausea; Sexual dysfunction (including anorgasmia (difficulty achieving an orgasm), erectile dysfunction, genital anaesthesia, ejaculation disorder, loss of libido etc.).
The common side effects of this combination are those of its individual drugs. For instance, the use of inhaled corticosteroids is associated with oral candidiasis, commonly known as yeast infection or thrush.
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
The fourth Maudsley Prescribing Guidelines International Conference Clinical Psychopharmacology in the time of COVID was held remotely on Wednesday 20th October 2021. Coinciding with publication of the 14th edition, the lead editors of the Guidelines and other key contributors, many of them leaders in their fields, have outlined the evidence ...
Fluconazole is an antifungal medication used for a number of fungal infections. [5] This includes candidiasis, blastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, dermatophytosis, and tinea versicolor. [5]
A branded version called Cortrosyn, which was created and developed by Organon and was approved by the FDA in 1970, and as of January 2017 was under the control of Amphastar Pharmaceuticals, [24] [25] and there were three generic versions under ANDAs, one for Mylan approved in 2009, [26] one for Sandoz/Novartis, approved in 2012, [27] and ...
Sandoz's Zarxio is biosimilar to Amgen's Neupogen (filgrastim), which was originally licensed in 1991. This is the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), which was passed as part of the Affordable Healthcare Act.